Alpha1H
Non-Muscle Invasive Bladder Cancer (NMIBC)
Phase 2Active
Key Facts
About Hamlet Biopharma
Hamlet Biopharma is a clinical-stage biotech advancing a novel oncology platform and repurposed immunology assets. Its lead candidate, Alpha1H, derived from the HAMLET complex, has shown promising efficacy in Phase II for non-muscle invasive bladder cancer (NMIBC). The company is also developing anakinra for recurrent urinary tract infections (rUTI) and severe bladder pain, having completed successful Phase II studies. Based in Lund, Sweden, Hamlet appears to be a publicly-traded, pre-revenue entity preparing for Phase III trials.
View full company profileTherapeutic Areas
Other Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Dabogratinib (Onc) | Tyra Biosciences | Phase 2 |
| NDV-01 | Relmada Therapeutics | Phase 2/3 |
| Fosciclopirox (Ciclopirox Prodrug) | CicloMed | Pre-clinical/Phase 1 |
| Vesique® (APL-1202) | Asieris Pharmaceuticals | Phase 3 |